10-Q: AEON Biopharma Reports Net Income Amidst Strategic Shift and Going Concern Uncertainty

Sentiment:

Quarterly Report 14 May 2025 8:10 PM

AEON Biopharma reports a net income for Q1 2025, driven by fair value adjustments, while navigating strategic changes and substantial doubt about its ability to continue as a going concern.

Capital raiseThe company states that further development of ABP-450 will require additional funding in the form of equity financings or debt.The company is actively attempting to secure additional capital to fund its operations.The company may seek to raise additional capital through the sale of public or private equity or convertible debt securities.

Worse than expectedDespite reporting a net income for the quarter, the company expresses substantial doubt about its ability to continue as a going concern, indicating a precarious financial position.The company received a notice of non-compliance from NYSE American due to a stockholders' deficit, signaling financial distress.

Summary

AEON Biopharma, Inc. reported a net income of $9.095 million for the quarter ended March 31, 2025, compared to a net loss of $118.018 million for the same period in 2024.
The company is shifting its focus to a biosimilar regulatory pathway for ABP-450, using AbbVie's Botox as a reference product.
AEON has experienced recurring losses and has substantial doubt about its ability to continue as a going concern, with cash and cash equivalents of $10.4 million and an accumulated deficit of $422.5 million as of March 31, 2025.
The company completed a public offering in January 2025, generating net proceeds of approximately $18.3 million.
Management identified material weaknesses in internal control over financial reporting, impacting risk assessment and segregation of duties.
Robert Bancroft was appointed as the new Principal Executive Officer, President, and CEO, effective April 29, 2025.
The company received a notice of non-compliance from NYSE American due to a stockholders' deficit and has submitted a plan to regain compliance by August 3, 2026.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's a reported net income, the going concern warning, NYSE non-compliance notice, and material weaknesses in internal control raise significant concerns. The strategic shift to a biosimilar pathway and new CEO appointment offer some hope, but the overall outlook is uncertain.

Positives

The company reported a net income of $9.095 million for the quarter ended March 31, 2025.
AEON secured $18.3 million in net proceeds from a public offering in January 2025.
The company is pursuing a biosimilar pathway for ABP-450, which could offer a more cost-effective alternative to Botox.
Robert Bancroft's appointment as CEO could bring new leadership and strategic direction.

Negatives

The company has an accumulated deficit of $422.5 million as of March 31, 2025.
There is substantial doubt about the company's ability to continue as a going concern.
The company received a notice of non-compliance from NYSE American due to a stockholders' deficit.
Material weaknesses in internal control over financial reporting were identified.

Risks

The company's ability to continue as a going concern is dependent on securing additional financing.
Failure to regain compliance with NYSE American listing standards could lead to delisting.
The development of ABP-450 as a biosimilar is subject to regulatory approval and market acceptance.
The company faces competition from existing botulinum toxin products.
Material weaknesses in internal control over financial reporting could impact the reliability of financial reporting.

Future Outlook

The company plans to develop and seek regulatory approval of ABP-450 as a biosimilar product in the United States. The company expects to continue to incur significant expenses and increasing net operating losses for the foreseeable future as it seeks regulatory approval and prepares for commercialization of ABP-450.

Management Comments

Marc Forth resigned as the Company's President and Chief Executive Officer, effective April 4, 2025, but will remain on the Board.
The Board named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies Mr. Forth’s successor.
Robert Bancroft was appointed as the Company's Principal Executive Officer, President, Chief Executive Officer and member of the Board, effective as of April 29, 2025.

Industry Context

The company is targeting the global therapeutic botulinum toxin market, estimated to be at least $3.3 billion based on AbbVie's reported global revenues for its therapeutic Botox segment for the fiscal year ended 2024. The shift to a biosimilar pathway reflects a strategy to compete with established products like Botox by offering a potentially lower-cost alternative.

Comparison to Industry Standards

AEON is pursuing a biosimilar pathway for ABP-450, aiming to compete with AbbVie's Botox, which dominates the therapeutic botulinum toxin market.
Unlike existing botulinum toxins with a single BLA for both therapeutic and cosmetic indications, AEON plans to obtain a separate BLA exclusively for therapeutic uses, potentially improving provider reimbursement.
Evolus, Inc. markets and sells Jeuveau (same botulinum toxin complex as ABP-450) for cosmetic indications, providing a benchmark for the safety and efficacy of the toxin.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and Chief Executive Officer	Marc Forth	Robert Bancroft	April 29, 2025	Marc Forth resigned to pursue another opportunity; Robert Bancroft was appointed as his successor.

Legal Proceedings

Odeon Capital Group LLC filed a lawsuit against the company alleging failure to pay a deferred underwriting fee of $1.25 million; the breach of contract claim is proceeding, with each party filing a summary judgment motion in March 2025.

Stakeholder Impact

Shareholders face potential dilution from future equity financings.
Employees may be affected by cost-cutting measures and strategic reprioritization.
Customers (patients) could benefit from a potentially lower-cost biosimilar alternative to Botox.
Suppliers and creditors face increased risk due to the company's going concern uncertainty.

Next Steps

The company will pursue the development of ABP-450 as a biosimilar product.
The company will prepare for a potential Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in the second half of 2025.
The company will take measures to regain compliance with NYSE American listing standards by August 3, 2026.
The company will actively attempt to secure additional capital to fund its operations.

Key Dates

Date	Description
December 20, 2019	Date of the original Daewoong License and Supply Agreement.
February 8, 2021	Date of the Warrant Agreement between Priveterra Acquisition Corp. and Continental Stock Transfer & Trust Company.
December 12, 2022	Date of the Business Combination Agreement between Priveterra Acquisition Corp., Priveterra Merger Sub, Inc. and AEON Biopharma, Inc.
July 21, 2023	Closing date of the acquisition of AEON Biopharma Sub, Inc. and name change from Priveterra Acquisition Corp. to AEON Biopharma, Inc.
March 19, 2024	Date of the Subscription Agreement with Daewoong for convertible notes and the Fourth Amendment to the License Agreement.
March 24, 2024	Issuance of the first convertible note to Daewoong.
April 12, 2024	Issuance of the second convertible note to Daewoong.
May 3, 2024	Announcement of preliminary top-line results from the Phase 2 trial with ABP-450 in chronic migraine.
July 9, 2024	Announcement of strategic reprioritization to pursue a 351(k) biosimilar regulatory pathway for ABP-450.
August 21, 2024	Effective date of the shelf registration statement on Form S-3.
January 6, 2025	Date of the underwriting agreement with Aegis Capital Corp. for a public offering.
January 7, 2025	Closing date of the public offering and Aegis exercised its over-allotment option.
February 3, 2025	Date the Company received a written notice of non-compliance from NYSE American.
February 24, 2025	Special stockholder meeting to authorize Stockholder Approval of the Warrants and approval of the Reverse Stock Split.
March 31, 2025	End of the reporting period for the 10-Q filing.
April 4, 2025	Effective date of Marc Forth's resignation as President and CEO.
April 19, 2025	The Board adopted the 2025 Employment Inducement Incentive Award Plan.
April 22, 2025	The Company received a notification from NYSE American that the Plan was accepted.
April 29, 2025	Effective date of Robert Bancroft's appointment as Principal Executive Officer, President, Chief Executive Officer and member of the Board.
August 3, 2026	Deadline for AEON Biopharma to regain compliance with NYSE American continued listing standards.

Keywords

AEON Biopharma, ABP-450, Biosimilar, Botox, Financial Results, Going Concern, Net Income, Public Offering, NYSE American, Robert Bancroft, Internal Control, Convertible Notes, Warrants, Daewoong

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.